Residency · Residency · Vascular Surgery

Venous Leg Ulcers: Wound Care and Surgical Management

Overview

Venous leg ulcers (VLUs) represent the majority of lower extremity ulcers, accounting for 70-80% of cases. They affect approximately 1-2% of the adult population, with prevalence increasing as people age. These ulcers predominantly occur in the gaiter area, especially around the medial malleolus. Without definitive correction of the underlying venous pathology, VLUs have a high recurrence rate, with 50-70% recurring within two years. The economic burden of managing VLUs in the United States exceeds $14 billion annually.

Pathophysiology of Venous Ulceration

The primary driving force behind venous ulceration is sustained ambulatory venous hypertension exceeding 40 mmHg. This elevated pressure causes capillary distension and increased permeability, allowing macromolecules such as fibrinogen to leak into the pericapillary space where it polymerizes into fibrin cuffs. These fibrin cuffs trap leukocytes, which become activated and release proteases and reactive oxygen species, perpetuating a chronic inflammatory state. This inflammation is characterized by overexpression of matrix metalloproteinases (MMPs) and degradation of growth factors essential for healing. Additionally, tissue hypoxia arises due to impaired oxygen diffusion and microcirculatory dysfunction. In this compromised environment, even minor trauma can trigger ulceration.

Evaluation

Clinical Assessment

Venous leg ulcers typically present as shallow wounds with irregular borders, surrounded by pigmentation changes and lipodermatosclerosis. They are located in the gaiter area, extending from the ankle to mid-calf, most commonly on the medial side. The wound base may be granulating or covered with fibrinous material and is rarely necrotic unless there is coexisting arterial disease. Accurate documentation of ulcer size is important for monitoring and can be done using tracings, photography, or digital planimetry. Clinical signs of infection to assess include increased pain, erythema, warmth, purulent drainage, and foul odor.

Differential Diagnosis

Differentiating VLUs from other ulcer types is critical. Arterial ulcers are typically painful, have punched-out edges, occur distally on toes or heels, have a pale base, and are associated with absent pulses. Neuropathic ulcers, often seen in diabetic patients, occur on the plantar surface, have callused borders, and are painless. Malignancy should be suspected in non-healing ulcers persisting beyond three months, especially if raised or rolled borders are present, warranting biopsy to rule out Marjolin ulcer. Vasculitis ulcers are painful, irregular, often bilateral, and may be accompanied by livedo reticularis. Pyoderma gangrenosum presents as rapidly enlarging ulcers with violaceous undermined borders and pathergy.

Vascular Assessment

Ankle-brachial index (ABI) measurement is mandatory before initiating compression therapy. An ABI of 0.8 or greater indicates it is safe to apply full compression. For ABI values between 0.5 and 0.8, modified or reduced compression should be used under specialist supervision. Compression is contraindicated when ABI is less than 0.5, and arterial disease must be addressed first. Duplex ultrasound is employed to map superficial, deep, and perforator vein reflux and to assess for venous obstruction. In cases where ABI is unreliable, such as in diabetic patients or those with calcified vessels, toe pressures or toe-brachial index (TBI) measurements are preferred.

Wound Assessment

The WIfI classification system is used to evaluate concurrent arterial disease. Wound cultures should be obtained only if clinical signs of infection are present, as superficial swabs have limited value; deep tissue cultures are preferred. Biopsy is indicated for ulcers that fail to heal after three months, have atypical appearances, raised edges, or when malignancy is suspected.

<image>Clinical photograph of a typical venous leg ulcer at the medial malleolus with surrounding hemosiderin deposition, lipodermatosclerosis, and atrophie blanche</image>

Compression Therapy

Principles

Compression therapy is the cornerstone of VLU management, as it accelerates healing and prevents recurrence. It works by counteracting venous hypertension, reducing superficial venous pressure and edema, enhancing calf muscle pump function, and decreasing capillary leakage and inflammation.

Compression Systems

Multi-layer bandaging is the most effective method for healing VLUs, providing sustained graduated compression. The four-layer bandage system (Profore) delivers approximately 40 mmHg of pressure at the ankle with graduated compression up the leg. Short-stretch bandages offer high working pressure and low resting pressure, making them ideal for ambulatory patients. Two-layer compression wraps, such as Coban 2-Layer, are easier to apply and provide acceptable efficacy. The Unna boot, which consists of zinc oxide-impregnated gauze covered with an elastic overwrap, is well tolerated and typically applied weekly. Compression stockings with 30-40 mmHg pressure primarily serve to maintain healing after ulcer closure, though ulcer kits involving two-stocking systems can be used during the treatment phase. Intermittent pneumatic compression devices serve as adjuncts for refractory ulcers or in immobile patients.

Compliance Challenges

Patient education is essential because ulcers tend to recur without ongoing compression. Barriers such as difficulty applying stockings, cost, discomfort, and skin sensitivity must be addressed. Tools like stocking donning aids and Velcro-wrap devices can improve compliance.

<image>Application sequence of a four-layer compression bandage system for venous leg ulcer management, showing each layer from orthopaedic wool to cohesive bandage</image>

Wound Bed Preparation (TIME Framework)

T — Tissue Management

Effective tissue management involves sharp debridement of devitalized tissue, fibrinous slough, and callused wound edges. For wounds with low exudate, autolytic debridement using moisture-retentive dressings is appropriate. Enzymatic debridement with agents such as collagenase can be used as an adjunct.

I — Infection/Inflammation Control

It is important to distinguish between colonization, which is present in all chronic wounds, and clinical infection. Topical antimicrobials targeting biofilm include cadexomer iodine, silver-containing dressings, and medical-grade honey. Systemic antibiotics are reserved for spreading cellulitis, sepsis, or confirmed deep infections. Managing biofilm requires serial sharp debridement combined with topical antimicrobials.

M — Moisture Balance

Maintaining a moist wound environment without causing maceration is critical. For wounds with high exudate, dressings such as alginate, hydrofiber (Aquacel), foam, or superabsorbent dressings are used. Low-exudate wounds benefit from hydrogel or hydrocolloid dressings. Protecting the periwound skin with barrier creams or films helps prevent irritation.

E — Edge Advancement

If wound edges are not advancing after four weeks of standard care, reassessment is necessary. Biopsy of non-healing edges should be performed to exclude malignancy. Advanced therapies should be considered if the wound area has not reduced by 30-40% at four weeks, as this predicts poor healing at 12 weeks.

Advanced Wound Therapies

Negative-Pressure Wound Therapy (NPWT)

NPWT applies sub-atmospheric pressure to the wound bed via a sealed foam or gauze dressing. This therapy removes exudate, reduces edema, promotes granulation tissue formation, and increases perfusion. It is particularly useful for large, deep, or heavily exudative ulcers and can be combined with instillation therapy (NPWTi-d).

Skin Substitutes and Cellular Therapies

Bilayered living cellular constructs such as Apligraf contain fibroblasts and keratinocytes to promote healing. Acellular dermal matrices like Oasis and Integra, as well as human skin allografts (cryopreserved or dehydrated), are also used. These therapies are most effective after adequate wound bed preparation and in conjunction with ongoing compression.

Skin Grafting

Split-thickness skin grafts (STSG) are employed for large ulcers once granulation tissue has formed. Pinch grafts, which involve transplanting small islands of full-thickness skin, can be performed in an office setting. Optimal outcomes are achieved when skin grafting is combined with correction of underlying venous reflux.

Surgical Management

Superficial Venous Ablation

The EVRA trial (2018) demonstrated that early endovenous ablation of superficial reflux combined with compression therapy results in faster ulcer healing (median 56 versus 82 days) and reduced recurrence compared to compression alone. Ablation should be offered early, ideally within two weeks of presentation, to patients with superficial reflux. All endovenous modalities are acceptable, including endovenous laser ablation (EVLA), radiofrequency ablation (RFA), foam sclerotherapy, and cyanoacrylate closure. Even in the presence of coexisting deep reflux, superficial ablation alone improves outcomes.

Perforator Interruption

Subfascial endoscopic perforator surgery (SEPS) has largely been replaced by percutaneous techniques for perforator interruption. Percutaneous ablation of incompetent perforators, either thermal or chemical, is considered when perforators larger than 3.5 mm with outward flow are adjacent to the ulcer bed. This approach is adjunctive, as evidence for standalone benefit is limited.

Deep Venous Reconstruction

For patients with post-thrombotic obstruction, iliac vein stenting guided by intravascular ultrasound (IVUS) has shown improved ulcer healing and reduced recurrence. Valve reconstruction procedures such as valvuloplasty or valve transplantation are investigational and available only at limited centers.

Fasciotomy and Fibrous Tissue Excision

Shave therapy involves excision of the ulcer base, including fibrotic tissue down to healthy fascia, followed by coverage with a split-thickness skin graft. This technique is effective for large, longstanding ulcers refractory to conservative management and addresses the chronic inflammatory nidus within the wound bed.

<image>Algorithm for management of venous leg ulcers showing initial assessment, compression therapy, wound care, indications for early endovenous ablation, and escalation to advanced therapies</image>

Recurrence Prevention

Prevention of VLU recurrence requires lifelong use of compression stockings, ideally providing 30-40 mmHg pressure, with a minimum of 20-30 mmHg. Correction of superficial venous reflux reduces recurrence rates from approximately 50% to 30%. Regular follow-up is necessary to identify and treat early recurrence. Patient education should emphasize leg elevation, exercise, skin moisturization, and recognition of early signs of recurrence. Weight management and treatment of comorbidities such as heart failure, obesity, and immobility also play important roles.

Clinical Pearls

Compression therapy remains the single most important intervention for venous ulcers, and if there is any doubt, it should be initiated after confirming an ABI of 0.8 or greater. If an ulcer has not reduced in area by 30-40% at four weeks, the treatment plan must be reassessed rather than continuing the same approach passively. All non-healing ulcers persisting beyond three months should be biopsied to exclude squamous cell carcinoma (Marjolin ulcer). Bilateral "cellulitis" in patients with venous disease is almost always venous eczema, and antibiotics are not the appropriate treatment. The EVRA trial has changed clinical practice by supporting early referral for endovenous ablation rather than waiting for ulcer healing before intervention. Patients with mixed arterial-venous ulcers (ABI 0.5-0.8) can still benefit from modified compression but require vascular specialist supervision. Pentoxifylline at 400 mg three times daily is an underutilized adjunct that improves venous ulcer healing independently of compression therapy.

References

• O'Donnell TF, et al. Management of venous leg ulcers: clinical practice guidelines of the SVS and the American Venous Forum. J Vasc Surg. 2014;60(2 Suppl):3S-59S.
• Gohel MS, et al. (EVRA trial) A randomized trial of early endovenous ablation in venous ulceration. N Engl J Med. 2018;378(22):2105-2114.
• Nelson EA, Bell-Syer SE. Compression for preventing recurrence of venous ulcers. Cochrane Database Syst Rev. 2014;(9):CD002303.
• Jull AB, et al. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012;(12):CD001733.
• Barwell JR, et al. (ESCHAR trial) Comparison of surgery and compression with compression alone in chronic venous ulceration. Lancet. 2004;363(9424):1854-1859.

Read this lecture as Markdown